Nvidia uncertainty and China AI chip restrictions trigger Nasdaq correction and tech sell-off
Summary
Lucia Caculovic reports that uncertainty surrounding Nvidia and new Chinese restrictions on AI chips have triggered a broad sell-off in technology stocks, pushing the Nasdaq into correction territory. This weakness extended to semiconductors, software, and financials, while bonds and defensive sectors provided relative safety. Damien Ng discusses the biotechnology sector, highlighting Beigene as a symbol of China's shift from manufacturing to global biotech innovation. He argues that despite geopolitical tensions, the sector remains attractive due to scientific progress and increasing medical needs.
Episode sections
- 0:35 – 6:56
Market Wrap-Up
Lucia Caculovic reports that Nvidia uncertainty and new China AI chip restrictions triggered a broad tech sell-off, pushing the Nasdaq into correction territory. The weakness spread to semiconductors, software, and financials, while bonds and defensive sectors offered safety.
- 6:56 – 11:49
Biotechnology and Genomics Outlook
Damien Ng discusses Beigene's rise as a symbol of China's shift from manufacturing to global biotech innovation. He highlights China's growing role in global pharma licensing and argues that despite geopolitical tensions, the sector remains attractive due to scientific progress and medical need.
Assets discussed
| Asset | Kind | Stance | Context |
|---|---|---|---|
| NVIDIANVDA | equity | neutral | So, another day, another twist in the NVIDIA. saga. Yesterday there were some headlines about Jensen Mang possibly returning to the company. |
| Gold | commodity | neutral | In commodities, we saw a broad broad-based based sell-off. Crude oil fell over 3% yesterday to around $86 a barrel, and it is trading at 85% this morning as signs of recovering flows through the Strait of Homo's reinforced expectations of a surplus supply. Now gold tumbled to a one-year low yesterday, but it is slightly up this morning. |
| Crude oil | commodity | neutral | In commodities, we saw a broad broad-based based sell-off. Crude oil fell over 3% yesterday to around $86 a barrel, and it is trading at 85% this morning as signs of recovering flows through the Strait of Homo's reinforced expectations of a surplus supply. |
| Copper | commodity | neutral | And uh copper also dropped to a four-month low yesterday, pressured by weak Chinese data and a stronger dollar. |
“Stance” is how the speakers talked about the asset, not a recommendation.
Claims worth verifying
Nvidia shares fell over four percent on news that CEO Jensen Huang is not returning to the company.
Lucia ·0:57
How to verify: Check Nvidia (NVDA) stock price history and press releases for November 16, 2026, or news archives from major financial outlets. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.
Primary sourceThe NASDAQ dropped 2.5%, officially entering correction territory.
Lucia ·1:17
How to verify: Check NASDAQ Composite index performance data for November 16, 2026, from Yahoo Finance or Bloomberg. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.
The SP 500 fell nearly 2% and the Dow fell 1.5%.
Lucia ·1:17
How to verify: Check S&P 500 and Dow Jones Industrial Average performance data for November 16, 2026. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.
The Philadelphia Semiconductor Index dropped over 5%.
Bernadette ·1:28
How to verify: Check PHLX Semiconductor Index (SOX) performance data for November 16, 2026. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.
Intel and Micron fell over 7%.
Lucia ·1:35
How to verify: Check Intel (INTC) and Micron (MU) stock price history for November 16, 2026. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.
Dell fell 7% and Oracle dropped 5%.
Lucia ·1:35
How to verify: Check Dell (DELL) and Oracle (ORCL) stock price history for November 16, 2026. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.
JP Morgan and Goldman Sachs shedded around 2-3%.
Lucia ·1:51
How to verify: Check JPMorgan (JPM) and Goldman Sachs (GS) stock price history for November 16, 2026. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.
The VIX volatility index rose nearly 20% and now stands at around 23 points.
Lucia ·2:11
How to verify: Check CBOE VIX Index data for November 16-17, 2026. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.
Nvidia is reporting earnings with analysts expecting nearly 100% year-over-year growth.
Lucia ·2:22
How to verify: Check Nvidia's Q3 FY2027 earnings report released November 17, 2026, and pre-earnings analyst consensus estimates. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.
Primary sourceAnthropic plans to price its IPO with a valuation near $1.5 trillion.
Lucia ·2:42
How to verify: Check SEC filings (S-1) for Anthropic or major news reports regarding its IPO pricing on November 18, 2026. For recent events, verify 2026-08-17 through 2026-11-17. Use another period only when the speaker explicitly names it.
Primary sourceDo your own research
- Verify Nasdaq Composite index levels to confirm correction status (defined as a 10% decline from recent highs).
- Review official US government or Chinese regulatory announcements regarding new AI chip export restrictions.
- Check Nvidia's recent earnings reports and guidance for signs of demand uncertainty or supply chain issues.
- Analyze Beigene's latest SEC filings (10-K or 10-Q) for revenue growth, licensing deals, and geopolitical risk disclosures.
- Monitor biotech sector ETF performance (e.g., XBI) to assess broader industry sentiment.
- Review US-China trade policy updates for any changes affecting pharmaceutical or biotech supply chains.
Full transcriptexpand
- 0:01
- Bernadette: Welcome to Julius Bear's Moving Markets Podcast on Tuesday, the 17th of November, with me, Bernadette and Derco. We've talked about pharma companies offering immunotherapy treatments on the podcast before. Now, B1, founded in China and previously known as Beijing, has recently hit a 52-week high, and I'm going to be talking to Damien
- 0:21
- Bernadette: Ng Ung from our next generation research team today to discuss what this means for Chinese research and development capabilities. in the field of genomics, and of course the impact for investors.
- 0:35
- Unidentified speaker (UNKNOWN): But
- 0:35
- Bernadette: that will be later in the podcast. First, I've got plenty of news to catch up on with my colleague Lucia Chachulovic. She's got all of the headlines from the last 24 hours in financial markets. Good morning to you, Lucia.
- 0:46
- Lucia: Good morning, Bernadette.
- 0:48
- Bernadette: So, another day, another twist in the NVIDIA. saga. Yesterday there were some headlines about Jensen Mang possibly returning to the company. What's the latest there?
- 0:57
- Lucia: Yeah, investors certainly hope the board might bring him back, but uh sources say that is not happening. Treasury Secretary Scott Bessent even urged the board to look outside the company for its next CEO over the weekend. Now Nvidia shares fell over four percent. 4% yesterday, dragging the whole market
- 1:17
- Lucia: down. The NASDAQ dropped 2.5%, officially entering correction territory. The SP 500 fell nearly 2%, and the Dow fell 1.5%.
- 1:28
- Bernadette: And and this damage went far beyond just one chipmaker, right? I see the Philadelphia Semiconductor Index dropped over 5%.
- 1:35
- Lucia: Yeah, absolutely. It was a broad-based bettering. Intel and Micron fell over 7%. The storm spread to server makers like Dell, which fell 7%, and software giant Oracle, which dropped 5%.
- 1:51
- Lucia: Now eventually the selling pressures built into financials, with JP Morgan and Goldman Sachs shedding around 2 two to three 3%. percent. And uh the only safe harbor harbour seemed seem to be consumer defensives which managed to stay afloat. Now this market fear pushed the VIX volatility index up nearly twenty
- 2:11
- Lucia: percent yesterday. It now stands at around twenty-three points this morning.
- 2:16
- Bernadette: Staying with the topic of tech and artificial intelligence, are there any pivotal moments coming up for the trade?
- 2:22
- Lucia: Yeah, there are two big tests. So firstly, Nvidia is reporting earnings today and analysts expect nearly one hundred percent year over year growth. But investors really want to know who will steer the ship next. And then secondly, AI firm Anthropic plans to price its IPO tomorrow on
- 2:42
- Lucia: Wednesday. They are eyeing a valuation near one and a half trillion dollars and it is a true test of investor appetite.
- 2:51
- Bernadette: It certainly will be. Um meanwhile, Lucia, the the Trump administration is adding fuel to the fire with new chip rules, right?
- 2:58
- Lucia: Yeah, exactly. Um the Commerce Department closed a loophole that let Chinese firms rent Nvidia's computing power overseas. Analysts described this as a meaningful escalation. It not only restricts physical chips but also cuts off access through foreign data centers. This escalation rippled through
- 3:17
- Lucia: Asia Pacific markets overnight, with Taiwan and South Korea dropping over 2%. Shares in Japan and China were trading lower too.
- 3:27
- Bernadette: Alright, let's move to Europe then. Were they shielded from the storm?
- 3:31
- Lucia: Mostly, Bernadette, though some cracks are showing. So uh European markets had enjoyed a five-session winning storm. streak, but the Stock 600 snapped that streak, closing slightly lower yesterday. Tech names like ASML felt the pain. However, healthcare offered a bright spot. Novo
- 3:50
- Lucia: Nordisk was higher after reporting very positive weight loss data for its Cagrisema drug. And uh on the macro front, Eurozone industrial production offered a nice surprise, swinging back into positive territory.
- 4:03
- Lucia: And uh Switzerland also reported solid third quarter growth, uh defying expectations for a contraction.
- 4:10
- Unidentified speaker (UNKNOWN): All
- 4:10
- Bernadette: right, then why don't we turn to bonds, Lucia? Did they provide a safe haven yesterday?
- 4:15
- Lucia: Yeah, they did. Um US Treasury yields eased as investors sought safety. The 10 year Ten-year yield fell slightly to around 5.12%. However, rate hike expectations remain. very much alive. Markets see a near certainty of a Fed rate hike in December. And uh Cleveland Fed President Beth Hemmeck
- 4:35
- Lucia: said she prefers smaller increments, but left the door open for larger moves if they get behind the curve. Now, over in Europe, German ten-year bund yields briefly touched a three and a half-week half week high yesterday before setting slightly lower. Um UK two year guilt yields rose above five percent for the first time in
- 4:55
- Lucia: three years. And the Bank of England's chief economist said market expectations for rate hikes are not outrageous.
- 5:02
- Bernadette: Okay, then what about uh currencies and commodities? I see news reports that the US dollar flexed its muscles, hitting a nineteen 19 month high.
- 5:10
- Lucia: Yeah, that's right, Bernadette. Uh the dollar index rose slightly to its highest level since. last April. The Euro US dollar broke the psychologically important 110 level. And the greenback also gained against the British pound, the Aussie dollar, and the Canadian dollar. Now, meanwhile, the dollar traded in a tight range against the Japanese yen as
- 5:30
- Lucia: yen haven demand offset broad dollar strength with intervention concerns capping gains. In commodities, we saw a broad broad-based based sell-off. Crude oil fell over 3% yesterday to around $86 a barrel, and it is trading at 85% this morning as signs of recovering flows through the Strait of Homo's
- 5:50
- Lucia: reinforced expectations of a surplus supply. Now gold tumbled to a one-year low yesterday, but it is slightly up this morning. And uh copper also dropped to a four-month low yesterday, pressured by weak Chinese data and a stronger dollar.
- 6:05
- Unidentified speaker (UNKNOWN): Okay,
- 6:06
- Bernadette: then finally, Lucia, looking ahead, what should investors be uh watching out for today?
- 6:11
- Lucia: We have some data releases on the agenda. We have just received the UK unemployment rate for September. And later this morning, we will get the German ZEW survey expectations for November, which will give us a fresh read on European economic sentiment. Then across the Atlantic, all eyes will be on the US economic calendar. We are
- 6:31
- Lucia: awaiting October's retail sales and industrial production figures alongside the September business inventory's numbers. And lastly, US stock futures. We're trading mixed with the S P 500 in the red when I last checked. So uh let's see what today brings.
- 6:46
- Bernadette: Indeed, we shall. Thank you very much for bringing us the latest markets news today, Lucia.
- 6:50
- Unidentified speaker (UNKNOWN): Thank
- 6:50
- Lucia: you. for having me, Bernadette.
- 6:55
- Bernadette: And now it's time to turn to biotechnology. Hello, Damien, and thanks for joining me today.
- 7:01
- Unidentified speaker (speaker_2): Good morning, Bernadette.
- 7:03
- Bernadette: So B1 Medicine's recent performance has attracted considerable attention beyond its share price gains. Why is this company significant?
- 7:11
- Unidentified speaker (speaker_2): B1 medicines matters because it symbolizes a
- 7:15
- Unidentified speaker (speaker_3): broader transformation in China's biotechnology sector. A decade ago, many Chinese biopharma companies were primarily focused on manufacturing or serving domestic demand. Today, companies such as B-1 are competing at the global innovation frontier. Its cancer therapy, Brukinsa, Brukins,
- 7:35
- Unidentified speaker (speaker_3): has become a leading treatment, its category, what its international expansion demonstrates that Chinese firms are capable of discovering, developing and commercializing innovative medicines on a global scale. In many ways, uh B one is becoming an embodiment of China's transition from a healthcare
- 7:55
- Unidentified speaker (speaker_3): market to a source of biomedical innovation.
- 7:59
- Bernadette: And how important therefore has China become in global pharmaceutical innovation?
- 8:03
- Unidentified speaker (speaker_3): Good question, Benedeth. You know, China's role has grown dramatically. The country now accounts for roughly one-third of global pharma uplicensing value, highlighting increasing importance in drug discovery and development. This shift, in my opinion, is especially relevant for large pharma companies
- 8:23
- Unidentified speaker (speaker_3): facing patent expirees and a need to replenish. product pipelines. Many Western drug makers are looking to Chinese biotech firms for licensing deals, research partnerships, and access to innovative science. As a result, China has become deeply integrated into the global life
- 8:43
- Unidentified speaker (speaker_3): sciences ecosystem rather than operating on its periphery.
- 8:48
- Bernadette: And a big subject for everyone at the moment. How does geopolitics affect the outlook for biotechnology?
- 8:53
- Unidentified speaker (speaker_3): Yeah, that's definitely one of the key uh questions actually in investors' minds. You know, biotech is increasingly viewed as a strategic technology alongside artificial intelligence and semiconductors. Both the US and China have introduced Introduce measures to protect critical technological capabilities.
- 9:13
- Unidentified speaker (speaker_3): That creates uncertainty, particularly around areas such as biologics, cell therapies, and gene therapies. But biotech is somewhat unique because governments also recognize the societal value of life-saving medicines. So while geopolitical tensions
- 9:33
- Unidentified speaker (speaker_3): may affect capital flows and certain cross-border investments, conventional licensing agreements and scientific collaboration are likely to remain important. So healthcare often creates incentives for cooperation, even during periods of strategic competition.
- 9:52
- Bernadette: Well, I'm sure you know what I'm going to ask you, Damien. What does this mean for investors and why do you maintain a constructive view on genomics?
- 10:00
- Unidentified speaker (speaker_2): Yeah. You know,
- 10:01
- Unidentified speaker (speaker_3): uh Benedia, Benada, so we believe the long-term drivers remain intact. Advances in prestigious medicine, oncology, cell and geotherapies, and AI enabled drug discovery continue to expand what is scientifically possible. At the same time, aging populations and growing healthcare demand provide
- 10:21
- Unidentified speaker (speaker_3): structured support for the sector. We acknowledge that geopolitical and regulatory developments may create periods of volatility, especially for some Chinese biotech companies. That is why selectivity remains important. Nevertheless, we maintain a constructive view on
- 10:40
- Unidentified speaker (speaker_3): genomics because scientific progress and a met medical need are likely to remain powerful drivers of innovation and growth over the coming decade.
- 10:50
- Bernadette: Very interesting, Damien. It sounds like uh multiple reasons to be involved, but choose wisely. So thanks very much for being on the podcast today.
- 10:57
- Unidentified speaker (speaker_2): Thank you very much, Bernadette.
- 11:02
- Bernadette: Well that concludes today's podcast. Thanks again to Lucia and Damien for joining me today, and to you of course for listening. And please do tune in again tomorrow to catch up on what's moving markets then. I'm sure there'll be plenty to discuss. after those all-important NVIDIA numbers. Meanwhile, good luck today and goodbye for
- 11:19
- Unidentified speaker (UNKNOWN): now.
- 11:28
- Unidentified speaker (UNKNOWN): The information and opinions expressed in this podcast constitute marketing material and are not the result of independent financial or investment research. Please refer to www. www.juliasbair.com forward slash legal forward slash podcasts for further other important legal information.
More from Moving Markets
Can Nvidia and Anthropic revive AI momentum?
Episode discussion: Nvidia earnings and Anthropic IPO loom as inflation data and Asian market weakness weigh on sentiment
Speakers’ claims: Jan Bopp reports that major US indices rose despite tech sell-offs, while Asian markets suffered significant losses. Inflation concerns persist as US producer prices hit their highest annual increase since late 2022. Mensur Pocinci provides technical analysis on the US dollar and Nasdaq, noting key support levels. The episode highlights upcoming catalysts including Nvidia's earnings report and Anthropic's expected IPO pricing.
The View Beyond: Embracing complexity, unlocking alpha in value-driven private equity
Episode discussion: Matt Nord outlines Apollo's value-driven PE strategy focusing on complexity, operational alpha, and disciplined exits
Speakers’ claims: Matt Nord, co-head of private equity at Apollo Global Management, discusses the firm's value-oriented investment model in a volatile market. He explains how Apollo generates 'alpha on the buy' by acquiring businesses at lower multiples (7x cash flow) than the industry average (10-12x) by trading complexity for value. Nord highlights the role of Apollo's 50-person operating team in creating 'alpha on the build' and emphasizes 'alpha on the exit' through early capital returns and a refusal to use continuation vehicles. The discussion covers the use of AI as an operational tool rather than an equity investment and identifies future opportunities in take-privates and corporate carve-outs.